drugset
drugset / Trial / NCT01856764

Topical Roflumilast in Adults With Atopic Dermatitis

NCT01856764 ↗

Phase 2 Completed 40 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effect of topical roflumilast on the reduction of atopic dermatitis lesions in adults with atopic dermatitis.

Timeline

Start
2013-06
Primary completion
2014-03
Completion
2014-03

Outcome

Missed primary endpoint

registry 0.5% Roflumilast Cream vs Vehicle Cream; p = 0.276; LS Mean Difference -0.55 (95% CI -1.5542 to 0.4574) NCT01856764 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Roflumilast Small molecule 0.5 % Topical

Indications

atopic eczema